Barclays PLC Kal Vista Pharmaceuticals, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 67,222 shares of KALV stock, worth $602,309. This represents 0.0% of its overall portfolio holdings.

Number of Shares

67,222

Previous 67,222 -0.0%

Holding current value

$602,309

Previous $778,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$9.46 - $15.39 $513,271 - $835,015	54,257 Added 418.49%	67,222 $778,000
Q2 2024 Aug 14, 2024	SELL	$10.35 - $12.49 $93,046 - $112,285	-8,990 Reduced 40.95%	12,965 $152,000
Q1 2024 May 15, 2024	SELL	$11.07 - $16.04 $227,776 - $330,039	-20,576 Reduced 48.38%	21,955 $260,000
Q4 2023 Feb 15, 2024	BUY	$7.58 - $12.25 $290,435 - $469,371	38,316 Added 909.04%	42,531 $521,000
Q3 2023 Nov 07, 2023	SELL	$8.95 - $11.35 $6,184 - $7,842	-691 Reduced 14.08%	4,215 $40,000
Q2 2023 Aug 03, 2023	SELL	$7.73 - $10.57 $58,029 - $79,348	-7,507 Reduced 60.48%	4,906 $44,000
Q1 2023 May 04, 2023	BUY	$6.3 - $8.39 $36,798 - $49,005	5,841 Added 88.88%	12,413 $97,000
Q4 2022 Feb 13, 2023	BUY	$4.2 - $14.24 $16,476 - $55,863	3,923 Added 148.09%	6,572 $45,000
Q3 2022 Nov 03, 2022	BUY	$9.85 - $16.83 $6,688 - $11,427	679 Added 34.47%	2,649 $38,000
Q2 2022 Aug 12, 2022	SELL	$8.16 - $15.1 $13,610 - $25,186	-1,668 Reduced 45.85%	1,970 $19,000
Q1 2022 May 16, 2022	SELL	$11.2 - $16.97 $283,897 - $430,155	-25,348 Reduced 87.45%	3,638 $54,000
Q4 2021 Feb 14, 2022	BUY	$12.36 - $18.28 $229,673 - $339,678	18,582 Added 178.6%	28,986 $383,000
Q3 2021 Nov 09, 2021	BUY	$17.11 - $24.49 $91,281 - $130,654	5,335 Added 105.25%	10,404 $181,000
Q2 2021 Aug 13, 2021	SELL	$23.12 - $29.91 $652,307 - $843,880	-28,214 Reduced 84.77%	5,069 $122,000
Q1 2021 May 13, 2021	BUY	$14.69 - $42.57 $287,968 - $834,499	19,603 Added 143.3%	33,283 $854,000
Q4 2020 Feb 11, 2021	SELL	$12.88 - $19.47 $12,596 - $19,041	-978 Reduced 6.67%	13,680 $260,000
Q3 2020 Nov 12, 2020	BUY	$9.83 - $13.99 $6,458 - $9,191	657 Added 4.69%	14,658 $185,000
Q2 2020 Aug 12, 2020	BUY	$6.75 - $12.89 $22,423 - $42,820	3,322 Added 31.11%	14,001 $169,000
Q1 2020 May 13, 2020	SELL	$5.8 - $18.56 $82,458 - $263,867	-14,217 Reduced 57.11%	10,679 $82,000
Q4 2019 Feb 10, 2020	BUY	$10.31 - $17.81 $70,747 - $122,212	6,862 Added 38.05%	24,896 $444,000
Q3 2019 Nov 14, 2019	SELL	$11.6 - $21.67 $57,686 - $107,764	-4,973 Reduced 21.62%	18,034 $209,000
Q2 2019 Aug 14, 2019	SELL	$18.44 - $30.89 $174,848 - $292,898	-9,482 Reduced 29.19%	23,007 $510,000
Q1 2019 May 15, 2019	SELL	$16.51 - $31.1 $500,071 - $941,987	-30,289 Reduced 48.25%	32,489 $930,000
Q4 2018 Feb 14, 2019	BUY	$16.21 - $24.06 $1.02 Million - $1.51 Million	62,707 Added 88319.72%	62,778 $1.24 Million
Q3 2018 Nov 14, 2018	BUY	$8.0 - $22.11 $568 - $1,569	71 New	71 $2,000
Q1 2018 May 15, 2018	SELL	$9.22 - $12.35 $12,437 - $16,660	-1,349 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$6.8 - $13.54 $9,173 - $18,265	1,349	1,349 $13,000

Others Institutions Holding KALV

# of Institutions

125

Shares Held

47.8M

Call Options Held

551K

Put Options Held

110K

View Full List

About KalVista Pharmaceuticals, Inc.

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $220M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

More about KALV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account